Drugs that contain Entrectinib
1. List of Rozlytrek drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(5 years from now) | |
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(11 years from now) | |
| US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(11 years from now) | |
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| US11253515 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(15 years from now) | |
| US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 15, 2024 |
NCE-1 date: 2023-08-16
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion
Dosage: CAPSULE;ORAL
ROZLYTREK family patents
32
United States
16
European Union
7
China
7
Korea, Republic of
6
Japan
6
Israel
6
Australia
5
Spain
5
Canada
5
Poland
4
Brazil
4
New Zealand
4
Taiwan, Province of China
4
Hong Kong
3
Mexico
2
Singapore
2
Argentina
2
EA
2
Hungary
2
Ukraine
2
Chile
2
Netherlands
1
Portugal
1
Russia
1
Norway
1
Philippines
1
South Africa
1
Slovenia
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic